P21 (P021): CNTF-Derived Peptide for Neurogenesis and Memory Research

What Is P21 (P021)?

P21, also designated P021, is a synthetic tetrapeptide derived from ciliary neurotrophic factor (CNTF) with the sequence Ac-DGGLAG-NH₂ in its original form, though the commonly referenced "P21" in neurogenesis research typically refers to the peptide that mimics the CNTF binding domain. The compound is specifically engineered to cross the blood-brain barrier (BBB) — a significant limitation of endogenous CNTF, which cannot penetrate the CNS when administered peripherally.

The development of P21 arose from research identifying CNTF's potent neurogenic and neurotrophic effects in preclinical models and the need for a BBB-permeable peptide analog. In animal studies, P21 has demonstrated robust stimulation of hippocampal neurogenesis, improvement in synaptic plasticity measures, and enhancement of cognitive performance. Its potential applications extend to age-related cognitive decline, neurodegenerative diseases, and Down syndrome-related intellectual disability research.

P21 is of particular interest as a research tool because it activates CNTF receptor signaling without the weight loss and systemic inflammatory effects associated with full-length CNTF administration, making it better tolerated in chronic research protocols.

Mechanism of Action

CNTF Receptor Pathway Activation

P21 acts as a functional mimic of CNTF at its receptor complex. The CNTF receptor consists of three components:

• •CNTFRα: The ligand-binding subunit (unique to the CNTF receptor)
• •gp130: Signal-transducing subunit shared with IL-6 family cytokines
• •LIFRβ: Signal-transducing subunit also shared with leukemia inhibitory factor receptor

P21 binding to this receptor complex initiates:

1. JAK-STAT signaling: Activation of JAK1/JAK2 tyrosine kinases phosphorylates STAT3, which dimerizes and translocates to the nucleus as a transcription factor

2. MAPK/ERK activation: Downstream activation of proliferative and pro-survival signaling

3. PI3K/Akt pathway: Neurotrophic and anti-apoptotic signaling cascade

4. NF-κB modulation: Inflammatory response regulation in neural tissue

Hippocampal Neurogenesis Promotion

Adult hippocampal neurogenesis — the generation of new neurons from neural stem/progenitor cells in the subgranular zone (SGZ) of the dentate gyrus — is a plastic process modulated by multiple factors. P21 appears to enhance neurogenesis through several mechanisms:

Proliferative effects on neural progenitor cells:

• •CNTF/JAK-STAT signaling promotes self-renewal of neural stem cells
• •Enhanced BrdU incorporation studies (a marker of cell division) confirm increased progenitor proliferation following P21 administration
• •Increased doublecortin (DCX) positive cell counts indicate more immature neurons entering the dentate gyrus

Differentiation and survival:

• •Promotes neuronal fate specification over glial differentiation
• •Enhances survival of newly born neurons through BDNF and NT-3 upregulation
• •Reduces apoptosis of immature neurons via Bcl-2/Bcl-xL upregulation

Synaptic integration:

• •New neurons generated under P21 influence show improved dendritic arborization
• •Enhanced long-term potentiation (LTP) at mossy fiber-CA3 synapses
• •Improved spine density on hippocampal pyramidal neurons

BDNF and Neurotrophic Synergy

A key aspect of P21's mechanism is upregulation of brain-derived neurotrophic factor (BDNF) and its cognate receptor TrkB:

• •CNTF receptor activation through JAK-STAT can upregulate CNTF and BDNF expression in a self-amplifying loop
• •Increased BDNF supports long-term potentiation and spatial memory consolidation
• •TrkB-MAPK signaling enhances dendritic complexity and spine maturation
• •The combination of increased neurogenesis AND enhanced BDNF signaling likely underlies P21's cognitive effects in rodent models

Tau Phosphorylation Reduction

In Alzheimer's disease and Down syndrome models, aberrant tau hyperphosphorylation is a hallmark of neurodegeneration. P21 research has revealed:

• •Significant reduction in tau phosphorylation at pathological epitopes (Ser396, Thr231) in rodent models
• •Mechanism involves upregulation of protein phosphatase 2A (PP2A) activity
• •PP2A is the primary phosphatase responsible for maintaining normal tau phosphorylation status
• •Reduced tau phosphorylation correlates with improved cognitive performance in treated animals

Published Research

All of the primary P021 literature comes from Khalid Iqbal's group at the New York State Institute for Basic Research in Developmental Disabilities (Staten Island), with collaborators at SUNY Downstate, UC Irvine, and the University of Bologna. Iqbal holds US patents on CNTF small-molecule peptide mimetics, which is stated in the papers' conflict-of-interest declarations and should be kept in mind when reading them (PMID 28368015).

Origin of the Compound

P021 was derived from the most active region of CNTF by epitope mapping, and an adamantylated glycine was added at the C-terminus to increase blood-brain-barrier permeability and slow exopeptidase degradation (PMID 28655344). The group's 2016 review describes it as a neurogenic and neurotrophic compound that enhances dentate-gyrus neurogenesis and memory by inhibiting leukaemia inhibitory factor (LIF) signalling and increasing BDNF expression, and that reduces abnormal tau hyperphosphorylation through a BDNF-mediated decrease in GSK-3β activity. The same review states that P021 is orally active with pharmacokinetics suitable for oral dosing and without the adverse effects associated with native CNTF or BDNF (PMID 27400746).

Cognitive Ageing in Rats

Bolognin and colleagues gave P021 orally to 22- to 24-month-old Fischer rats. Treatment reduced the age-dependent decline in learning and memory, inhibited the age-related deficit in neurogenesis, increased BDNF expression, restored synaptic deficits in cortex and hippocampus, and, by in vivo magnetic resonance spectroscopy, reduced hippocampal myo-inositol, which was elevated in aged versus young animals (PMID 24702821).

Alzheimer's Disease Models

In 3xTg-AD mice treated orally for 12 months from 9-10 months of age, P021 reduced tau hyperphosphorylation at major neurofibrillary-pathology sites, lowered soluble Aβ with a trend toward reduced plaque load in CA1, and rescued deficits in cognition, neurogenesis, and synaptic plasticity; the authors attributed the effect to increased BDNF and decreased GSK-3β activity (PMID 25046994). A prevention study started P021 in the diet at 3 months, before overt pathology, and continued to 21 months; treatment prevented dendritic and synaptic deficits, boosted neurogenesis, and reversed cognitive impairment (PMID 28655344).

Down Syndrome Model

In the Ts65Dn mouse model of Down syndrome, prenatal-to-early-postnatal P021 rescued developmental delay in pups and hippocampus-dependent memory impairment in adulthood, prevented presynaptic protein deficit, decreased GSK-3β activity, and increased BDNF and phosphorylated CREB in both 3-week-old and ~7-month-old animals (PMID 28368015).

CDKL5 Deficiency Disorder

The most recent application is outside the Iqbal group's own models: a 2024 study from the University of Bologna tested the CNTF peptide mimetic in in vitro and in vivo models of CDKL5 deficiency disorder, a severe epileptic encephalopathy (PMID 39592934).

What Has Not Been Published

There are no published human studies of P021, no independent replications of the neurogenesis findings by groups without a stake in the compound, and no long-term potentiation electrophysiology data in the peer-reviewed literature that we could locate. Statements about LTP magnitude, Morris water maze path efficiency, or fold-changes in BrdU-labelled neurons that circulate on supplier sites are not traceable to a PubMed record.

Research Specifications

• •Molecular formula: Varies by specific P21 analog; typically small tetrapeptide with MW ~300-500 Da
• •Classification: Nootropic research peptide (BBB-permeable CNTF mimetic)
• •Primary target: CNTFRα/gp130/LIFRβ receptor complex
• •Secondary targets: JAK1/2, STAT3, MAPK/ERK, PI3K/Akt
• •Plasma half-life: Estimated 30-60 minutes (limited published pharmacokinetic data)
• •BBB penetration: Documented in rodent studies
• •Available forms: Lyophilized powder
• •Reconstitution: Sterile water or sterile saline
• •Storage (lyophilized): -20°C, protected from moisture
• •Storage (reconstituted): -80°C for long-term; 4°C for 1 week maximum
• •Target purity: ≥98% by HPLC
• •Classification: For laboratory research use only (

Practical Research Considerations

Handling

P021 is supplied lyophilised; the adamantylated C-terminal glycine was added specifically to slow exopeptidase degradation and improve permeability (PMID 28655344), but reconstituted solutions should still be aliquoted and protected from repeated freeze-thaw. This article does not give dosing or administration protocols; the cited studies describe their own regimens (chronic oral administration in diet or drinking water in the ageing and 3xTg-AD work) and should be consulted directly.

Study Design Considerations

Neurogenesis validation:

• •BrdU (5'-bromo-2'-deoxyuridine) injection 2 hours post-peptide to label dividing progenitors
• •Doublecortin (DCX) immunostaining at sacrifice for immature neurons
• •NeuN staining for mature neuron counts
• •Ki67 staining for actively dividing cells (no BrdU required)

Functional validation:

• •Allow 4-6 weeks post-BrdU for newly born neurons to mature before cognitive testing
• •Battery should include hippocampus-dependent (spatial memory) and hippocampus-independent (cued tasks) measures for specificity

Controls:

• •Vehicle control (saline) matched for injection stress
• •Positive control (standard learning-enhancing compound)
• •Negative control for hippocampal neurogenesis (irradiation or temozolomide) if attributing cognitive effects to neurogenesis

Safety Profile and Interactions

Preclinical Safety Data

The published safety information is limited to what the efficacy papers report. The 2016 review states that P021 lacks the adverse effects associated with native CNTF or BDNF and has pharmacokinetics suitable for oral administration (PMID 27400746); the 3xTg-AD and ageing studies used chronic oral treatment for 12 months or longer without reporting treatment-related toxicity (PMID 25046994, PMID 24702821). No formal toxicology study, cytokine panel, or organ histopathology report for P021 has been published separately, so claims of a "clean" safety profile rest on the absence of reported problems in efficacy studies run by the compound's originators, not on independent safety testing.

Theoretical Concerns

JAK-STAT pathway activation: Sustained activation of STAT3 (one mechanism of CNTF receptor signaling) has been associated with oncogenic potential in non-neuronal tissues. Long-term safety profiling in chronic studies is important, though neurogenesis-relevant doses likely provide a wide safety margin.

Dose-dependent astrogliosis: Very high doses of CNTF receptor activators can promote astrocyte proliferation. This has not been widely reported for P21 at cognitive-enhancement doses but warrants monitoring in long-term studies.

Comparison to Related Compounds

P21 vs. Full-Length CNTF

The comparison illuminates why the peptide fragment is often preferred for research:

P21 vs. BDNF

BDNF is the most studied neurotrophin for hippocampal function, but has significant limitations as a research compound:

• •BDNF does not cross the BBB (large protein)
• •P21 indirectly upregulates BDNF, providing a BBB-permeable route to enhanced BDNF signaling
• •TrkB agonist peptides offer a more direct comparison; P21 and TrkB agonists show overlapping but distinct cognitive effects
• •P21 may have advantages in neurogenesis (progenitor proliferation) while BDNF is stronger for synaptic strength in mature neurons

P21 vs. Semax

Both P21 and Semax are neuroprotective/cognitive-enhancing peptides with BDNF-upregulating properties:

P21 vs. Dihexa

Both are potent cognitive enhancers in rodent models but with entirely different mechanisms:

• •Dihexa acts as an HGF receptor (MET) agonist with synaptogenic properties (dendritic spine formation)
• •P21 drives neurogenesis (new cell formation) and neurotrophic factor expression
• •The two mechanisms are complementary: P21 for neurogenesis, Dihexa for synaptic density
• •Combined protocols have been explored in aging and neurodegeneration models

Relevance to Human Conditions

Alzheimer's Disease

P21 targets several pathological features of Alzheimer's disease:

1. Hippocampal neurogenesis deficit: AD brains show reduced neurogenesis; P21 may help compensate

2. BDNF depletion: BDNF levels are reduced in AD brains; P21 upregulates BDNF

3. Tau hyperphosphorylation: P21 reduces pathological tau phosphorylation in animal models

4. Synaptic loss: Enhanced BDNF and neurogenesis may partially offset synaptic pruning

The Down syndrome-Alzheimer's link makes P21 particularly relevant, as all individuals with trisomy 21 develop AD-like pathology by middle age.

Post-Traumatic Brain Injury

Hippocampal neurogenesis is suppressed following TBI, contributing to post-injury cognitive deficits:

• •P21 administration in TBI models enhances recovery of hippocampal neurogenesis
• •Improved spatial memory performance at 2-8 weeks post-injury in P21-treated animals
• •Possible neuroprotective role through CNTF receptor signaling in surviving neurons

Depression and Stress-Related Disorders

Neurogenesis suppression by chronic stress is implicated in depression etiology:

• •Stress hormones (glucocorticoids) suppress hippocampal neurogenesis
• •Most antidepressants require neurogenesis for their behavioral effects
• •P21's neurogenesis-enhancing properties suggest potential antidepressant-like effects
• •Limited studies show reduced immobility in forced swim tests (depression proxy) in P21-treated animals

Internal Research Tools

For researchers working with P21, Peptides.SO provides:

• •Peptide Calculator: Calculate precise reconstitution volumes and dosing schedules
• •Stack Builder: Design multi-peptide cognitive enhancement research protocols

Related research compounds for neurogenesis and cognitive research:

• •Dihexa — HGF receptor agonist for synaptogenesis research
• •Semax — ACTH analog for neuroprotection and BDNF upregulation
• •BPC-157 — systemic repair peptide with neurological applications

P21 (P021) in Translational Neuroscience: Context and Limitations

Understanding P21's position in the neurogenesis research landscape requires context about the broader CNTF biology it's derived from and why a fragment-based approach was pursued.

Why a CNTF Fragment Rather Than CNTF Itself?

Ciliary neurotrophic factor (CNTF) is a pleiotropic cytokine with potent effects on neuronal survival, differentiation, and plasticity — but clinical translation of full-length CNTF has been severely limited by two problems:

1. Blood-brain barrier impermeability: CNTF (MW ~23 kDa) does not effectively cross the BBB when administered peripherally. Direct CNS administration (intracerebroventricular or intranasal) is used in animal research but has obvious translational hurdles

2. Systemic side effects: Phase I/II trials of recombinant CNTF for ALS and other conditions revealed problematic systemic effects (weight loss, anorexia, inflammatory responses) mediated by peripheral CNTF receptors

P21 was designed to address both problems simultaneously. As a small tetrapeptide (~400 Da), P21 crosses the BBB substantially better than full-length CNTF, and its limited sequence reduces but doesn't eliminate off-target activity through peripheral CNTF receptors. Research studies have validated CNS penetration after peripheral administration in rodents.

The Hippocampal Neurogenesis Mechanism in Detail

P21's most-studied neurobiological effect is promotion of adult hippocampal neurogenesis (AHN) — specifically the proliferation and survival of neural progenitor cells (NPCs) in the subgranular zone (SGZ) of the dentate gyrus. This mechanism is particularly relevant to:

• •Cognitive aging: AHN declines with age in parallel with memory function decline; compounds that preserve AHN have been studied as potential age-related cognitive intervention targets
• •Antidepressant research: Multiple antidepressant drugs (SSRIs, ketamine) promote AHN as part of their mechanism; P21 offers a neurogenesis-targeting comparator without monoamine effects
• •Down syndrome research: Trisomy 21 is associated with impaired neurogenesis and dendritic arborization; P21 has been studied specifically in Ts65Dn mouse models of Down syndrome

The mechanistic evidence suggests P21 promotes neurogenesis through combined stimulation of the CNTFR/STAT3/BDNF pathway and simultaneous tau dephosphorylation — addressing two distinct molecular features common to neurodegeneration. This dual action makes it useful as a research probe for experiments trying to disentangle these mechanisms.

Comparison: P21 vs. Other Neurogenesis Research Tools

This comparison illustrates why P21 occupies a distinct niche in neurogenesis research: it accesses CNTFR signaling (unlike Dihexa or Semax) while maintaining reasonable CNS access (unlike full-length CNTF or BDNF).

Study Design Considerations for P21 Neurogenesis Research

Researchers measuring neurogenesis outcomes with P21 should note:

• •BrdU/EdU labeling timing: Neural progenitor cell proliferation peaks 1-3 days after P21 administration in rodent studies; BrdU incorporation should be measured at peak exposure periods. Survival labeling (measuring cells that persist 4 weeks post-injection) shows the functional integration component
• •Dose and route: Intranasal administration has been shown to achieve CNS exposure at doses that minimize systemic exposure; subcutaneous administration has also been used with comparable CNS penetration data
• •Controls for cognitive testing: The Morris water maze and novel object recognition task are the most common behavioral endpoints in P21 neurogenesis research; ensure proper handling habituation and counterbalanced trial orders to reduce confounders
• •Tau phosphorylation timepoints: P21's tau dephosphorylation effects appear most robust at epitopes associated with early tangle formation (Thr231, Ser202); researchers measuring multiple tau epitopes should include both early and late phosphorylation markers

P21 (P021) Research Pricing: What the Platform Shows (September 2026)

P21 is a thinly supplied compound. Computed from the peptides.so listings table on 20 September 2026 (list prices of at least $5), the platform holds six product rows under the P21/P021 name, and the two with the most suppliers are:

Fewer than ten suppliers list the compound in any form, so there is no platform-grade median; treat the figures above as a snapshot rather than a market price. Vial sizes are inconsistent across rows (1 mg to 10 mg, plus a 10-vial pack row at $79 to $750), so compare per milligram on the P21 compound page.

Sourcing notes for P21:

• •P21 and P021 are the same tetrapeptide; verify sequence and molecular weight on the certificate of analysis before ordering
• •With this few suppliers, stock is intermittent; the compound page shows current status
• •See the COA Interpretation Guide for documentation evaluation

Frequently Asked Questions: P21 (P021) Research

Q: What is the difference between P21 and P021?

P21 and P021 are two designations for the same synthetic tetrapeptide derived from ciliary neurotrophic factor (CNTF). In research literature they are used interchangeably. The "P021" designation is more common in Alzheimer's disease and Down syndrome research contexts (particularly papers from the Lahiri and Martinez-Coria groups), while "P21" appears more frequently in neurogenesis literature.

Q: How does P21 differ from full-length CNTF?

Full-length CNTF is a large cytokine (~22 kDa) that does not cross the blood-brain barrier (BBB) when administered peripherally. P21 is a small tetrapeptide (~400 Da) engineered to retain the CNTF receptor-binding domain while achieving BBB penetration. Unlike CNTF, P21 does not cause significant weight loss or inflammatory cytokine responses, making it better suited to chronic neurogenesis research protocols.

Q: What animal models have been used in P21 research?

P21 research has been conducted primarily in: (1) transgenic Alzheimer's mouse models (3xTg-AD, J20), (2) trisomy 16 mouse models of Down syndrome, (3) normal aged rodents for cognitive decline studies, and (4) TBI (traumatic brain injury) models. All data is preclinical; no human trials have been completed.

Q: What reconstitution protocol is used for P21 in research?

Lyophilized P21 is typically reconstituted in sterile bacteriostatic water (0.9% benzyl alcohol) or phosphate-buffered saline (PBS). Published animal research has used concentrations ranging from 0.5–2 mg/mL. Use the Peptides.SO Reconstitution Calculator to determine precise volumes. Refer to the How to Reconstitute Peptides guide for full protocol.

Q: Is P21 FDA-approved?

No. P21 is not FDA-approved for any application. It is an investigational research compound used exclusively in preclinical laboratory studies. It is classified for Research Use Only (RUO) and should not be administered to humans outside of approved clinical trials.

Q: What cognitive metrics are typically tracked in P21 research?

Standard measures in published P21 studies include: Morris Water Maze performance (spatial learning and memory), Novel Object Recognition (NOR) test, hippocampal neurogenesis quantification via BrdU/Ki67/DCX immunostaining, BDNF protein levels by ELISA, and phospho-tau (AT8 epitope) staining. Researchers may also use fear conditioning, radial arm maze, and electrophysiology (LTP measurement).

References

1. Bolognin S, Buffelli M, Puoliväli J, Iqbal K. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging. 2014;35(9):2134-2146. PMID 24702821

2. Kazim SF, Blanchard J, Dai CL, et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2014;71:110-130. PMID 25046994

3. Kazim SF, Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Mol Neurodegener. 2016;11(1):50. PMID 27400746

4. Kazim SF, Blanchard J, Bianchi R, Iqbal K. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome. Sci Rep. 2017;7:45561. PMID 28368015

5. Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. 2017;9(1):45. PMID 28655344

6. Mottolese N, Loi M, Trazzi S, et al. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. J Neurodev Disord. 2024;16(1):65. PMID 39592934

Important Research Disclaimer

P21 is a research-stage compound that has not been approved for any clinical application in any jurisdiction. All data referenced in this article comes from preclinical studies (primarily rodent models), and translation to human efficacy and safety is unknown. This content is intended solely for scientific education and does not constitute medical advice. P21 should only be studied in appropriately controlled research settings with proper ethical oversight.

For research purposes only. Not for human use outside of approved clinical studies and authorized research protocols.

---

Further Reading:

• •PE-22-28: Complete Research Profile — Spadin Analog, TREK-1 Blocker, and Rapid-Onset Antidepressant Peptide for Nootropic Research (2026)
• •Dihexa: HGF Receptor Agonist for Cognitive and Synaptogenic Research
• •Semax: ACTH(4-10) Analog for Neuroprotection and Cognitive Research
• •Epitalon (AEDG Peptide): The Pineal Tetrapeptide in Telomerase and Aging Research
• •Reconstitution Calculator
• •Peptide Stack Builder